BizJournals Portfolio
Jul 23 2008 12:00am EDT

Questcor: From Orphan Drug To Orphan Stock?

Blaise Zerega can't fathom an 1,800% price hike.  Russ Mitchell's examination yesterday of why Questcor Pharmaceuticals raised the price of a drug used to treat infantile epilepsy from $1,600 per vial to $23,000 per vial helps set the stage for Congressional hearings tomorrow. But in the meanwhile, the company's share price is already taking a hit, down 9% to $4.57 as of this posting. What if it QCOR shares eventually fell 1,800%? Instant karma, anyone?

. □


blog comments powered by Disqus
Real Business, Real Results

Did anyone at Microsoft ever watch the (gasp!) offensively funny show Family Guy?

Ex-Morgan Stanley exec Zoe Cruz is now heading her own hedge fund. Are Wall Street's leaders done?

Martha, Bernie and Skilling know that what you wear for court can go a long way in public perception.

spotlight on

Health Care

Bad to the Bone No More

Companies such as General Mills say they're stepping up efforts to change employees' bad behavior and promote healthier lifestyles. Read More